S
San-Qi Zhang
Researcher at Xi'an Jiaotong University
Publications - 72
Citations - 977
San-Qi Zhang is an academic researcher from Xi'an Jiaotong University. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 15, co-authored 59 publications receiving 596 citations.
Papers
More filters
Journal ArticleDOI
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Hao Zhang,Hong-Yi Zhao,Xiao-Xiao Xi,Yan-Jie Liu,Minhang Xin,Shuai Mao,Jun-Jie Zhang,A-Xin Lu,San-Qi Zhang +8 more
TL;DR: The discovery of small molecule EGFR degraders based on the proteolysis targeting chimera (PROTAC) strategy demonstrated that compounds 2 and 10 could serve as effective EGFRdel19-targeting degrader in HCC827 cells.
Journal ArticleDOI
Small molecule selenium-containing compounds: Recent development and therapeutic applications.
Hongyan Chuai,San-Qi Zhang,Huan-Rong Bai,Jiyu Li,Wang Yang,Jiajia Sun,Ergang Wen,Jiye Zhang,Minhang Xin +8 more
TL;DR: More than 110 Se-containing compounds were selected as representatives which showed potent activities such as anticancer, antioxidant, antifibrolytic, antiparasitic, antibacterial, antiviral and antifungal and central nervous system related effects as discussed by the authors.
Journal ArticleDOI
Discovery of potent small molecule PROTACs targeting mutant EGFR.
Hong-Yi Zhao,Xue-Yan Yang,Hao Lei,Xiao-Xiao Xi,Shemin Lu,Jun-Jie Zhang,Minhang Xin,San-Qi Zhang +7 more
TL;DR: This work designed and synthesized a set of EGFR-targeting small molecule PROTACs which showed promising efficacy and identified that ubiquitination was indispensable in the degradation process, and found that the degradation was related to autophagy.
Journal ArticleDOI
Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.
Xiao-Meng Wang,Jing Xu,Yi-Ping Li,Huan Li,Congshan Jiang,Guang-De Yang,Shemin Lu,San-Qi Zhang +7 more
TL;DR: The results suggest that the title compounds are potent anticancer agents.
Journal ArticleDOI
Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors
Hao Lei,Shu Fan,Hao Zhang,Yan-Jie Liu,Yuan-Yuan Hei,Jun-Jie Zhang,Aqun Zheng,Minhang Xin,San-Qi Zhang +8 more
TL;DR: Molecular docking indicated that the introduction of a cyclopropylsulfonamide group in D9 led to the formation of additional two hydrogen bonds with mutant Ser797 which played key roles in generating efficient EGFRL858 R/T790 M/C797S inhibitory activity.